This is a bet on antibiotic-free animal nutrition scaling from lab science to industrial execution, because Aviwell is pairing microbiome products with an AI engine designed to shorten development cycles.
French startup Aviwell has raised EUR 11 million in Series A funding. The round was led by Blue Revolution Fund, with participation from Blast.Club, SWEN Capital Partners, Elaia and MFS Investment Management, according to an announcement reported by FinSMEs.
What Aviwell is building
Aviwell develops microbiome-based feed additives for poultry and aquaculture, targeting the structural shift toward antibiotic-free production and tighter sustainability expectations in animal protein supply chains.
At the core of the approach is Aneto™, an AI-powered platform that identifies modes of action within native bacterial ecologies. Aviwell says the platform is intended to improve animal performance, immunity and feed efficiency, while also reducing the time and cost required to bring microbiome-based feed solutions to market.
Use of proceeds: from discovery to scale-up
Aviwell said the EUR 11 million will be used to:
- Advance poultry and aquaculture products from discovery into scale-up
- Expand Aneto™ services, effectively productising the platform beyond internal R&D
- Deepen commercial partnerships, shifting focus from validation to repeatable go-to-market execution
The operational message is clear: the company is moving from proving scientific efficacy to building a manufacturing and commercial system that can support larger volumes and consistent customer deployment.
Why this round matters now
The deal fits a broader investment pattern in aquaculture and agrifood innovation: in 2025, sector data pointed to higher total investment value despite fewer deals, suggesting investors are concentrating capital into fewer, conviction-led rounds. Aviwell’s raise has been highlighted alongside other recent agritech financings, underscoring that animal nutrition and aquaculture remain active pockets even as venture selectivity increases.
For strategic buyers and incumbent nutrition players, the signal is that microbiome solutions are becoming investable at scale when paired with platforms that can accelerate iteration and support defensible product pipelines.
Execution watchpoints
Aviwell’s next phase is less about the promise of AI and more about delivery. Key risks and pressure points are typical for the category:
- Scale-up and consistency: microbiome products can be sensitive to production conditions, and performance must hold across farms, geographies and feed regimes.
- Commercial adoption: customers will demand measurable ROI in feed conversion, animal health and mortality, not just antibiotic-reduction narratives.
- Regulatory and claims discipline: moving from R&D to market-facing products requires careful substantiation and compliant positioning across target markets.
If Aviwell can translate Aneto’s discovery advantage into repeatable, scalable products and durable partnerships, this Series A positions it to compete in a fast-tightening market for antibiotic-free, high-efficiency animal nutrition.